sacituzumab govitecan
gilead sciences
['bcsm', 'breast', 'sacituzumab', 'mbc']
a 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and her2-negative metastatic breast cancer. #mbc #bcsm #asco22 
Oncology news and insights from leading researchers and cancer centers.